Faculty
Plenary Sessions
PL1-1
Chia-Ming Chu Taoyuan Natural History of Acute and Chronic HBV Infection
PL1-2
Giovanni Raimondo Messina Epidemiology and Clinical Significance of Occult HBV Infection/span>
PL1-3
Junko Tanaka Hiroshima Pathway from the Epidemiological Point of View; Moving towards the Elimination of HBV & HCV in Japan
PL1-4
John Ward Atlanta Global Epidemiology and Prevention of Chronic Hepatitis B Infection
PL2-1
Koichi Watashi Tokyo Cell Entry Inhibition as an Antiviral Strategy
PL2-2
Jianming Hu Hershey Complete and Incomplete HBV Particles
PL2-3
Man-Fung Yuen Hong Kong Recent Development of Capsid Modulators/ Inhibitors as New Antiviral Agents
PL2-4
Chau-Ting Yeh Taoyuan Eliminating cccDNA: Methods and Difficulties
PL3-1
Percy A. Knolle Munich The Liver Microenvironment and HBV Immunity
PL3-2
Laura Pallett London Manipulation of the Innate-adaptive Immune Cell Axis in Chronic HBV Infection
L3-3
Mi-Hua Tao Taipei Cure CHB via Targeting Adaptive Immune Response: Animal Experience
PL3-4
Antonio Bertoletti Singapore T Cell Therapy for Chronic HBV Infection
PL4-1
Mei-Hsuan Lee Taipei Epidemiology and Risk Assessment of Hepatitis C virus Infection in Taiwan
PL4-2
Chen-Hua Liu Taipei Current Treatment of HCV
PL4-3
Ming-Lung Yu Kaohsiung Unmet Needs of Chronic Hepatitis C after SVR
PL4-4
Geoffrey Dusheiko London How to Achieve Global HCV Elimination by 2030?
PL5-1
Yasuhito Tanaka Nagoya Advances in the Serologic and Virologic Diagnosis of HBV Infection
PL5-2
Shiou-Hwei Yeh Taipei Application of Circulating DNA to HBV Induced Liver Pathogenesis
PL5-3
Hwai-I Yang Taipei Application of HCC Risk Scores in Management of CHB Patients
PL5-4
Grace Wong Hong Kong Non-invasive Prediction of HBV Treatment Outcomes Including HCC
PL6-1
Camille Sureau Paris HDV Virology and The Novel Therapy for Chronic Hepatitis D
PL6-2
Jaw-Ching Wu Taipei Mechanisms of Large Hepatitis Eelta Antigen Induced Epithelial-mesenchymal Transition: Implications of Novel Therapy
PL6-3
Davaadorj Duger Ulaanbaatar Taiwan-Mongolian Collaboration to Control HDV Infection in a Hyperendemic Area
PL6-4
Chien-Wei Su Taipei Natural History of Chronic Hepatitis D Virus Infection
PL7-1
Henry Lik-Yuen Chan Hong Kong Unmet Needs of CHB after NUC Treatment
PL7-2
Tai-Chung Tseng Taipei Management of CHB Sub-populations with Grey Zone Treatment Indications
PL7-3
Yi-Cheng Chen Taoyuan NUC for CHB: Discontinued Versus Continuous Strategy
PL7-4
Chun-Jen Liu Taipei Reactivation of HBV in Special Clinical Settings: Risk and Management
PL8-1
Ryosuke Tateishi Tokyo Advance in Radiofrequency Ablation Therapy for HCC
PL8-2
Yoon-Jun Kim Seoul Advance in Drug-elution Bead TACE and SIRT for HCC
PL8-3
Ji-Hong Hong Taoyuan Proton Beam Therapy for HCC
PL8-4
Ann-Lii Cheng Taipei Advance in Immune Checkpoint Inhibitors for HCC
PL9-1
Mei-Hwei Chang Taipei Global Strategies of Hepatitis B Vaccination: The Past, Present and Future
PL9-2
Yong Poovorawan Bangkok The Implementation of HBV Vaccination in SouthEast Asia
PL9-3
Ayano Inui Yokohama How to Convince People to Implement Universal Vaccination in a Low-endemic Area?
PL9-4
Huey-Ling Chen Taipei Elimination of Mother-to-Child Transmission of HBV